Cantourage Group SE
ISIN: DE000A3DSV01
WKN: A3DSV0
10 Oktober 2024 08:00AM

EQS-News: The medical cannabis market is booming: Cantourage Group SE reports record quarter in third quarter of 2024

Cantourage Group SE · ISIN: DE000A3DSV01 · EQS - Company News
Land: Deutschland · Primärmarkt: Deutschland · EQS News ID: 2005489

EQS-News: Cantourage Group SE / Key word(s): Quarter Results/Development of Sales
The medical cannabis market is booming: Cantourage Group SE reports record quarter in third quarter of 2024

10.10.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.

 

The medical cannabis market is booming: Cantourage Group SE reports record quarter in third quarter of 2024

  • Sales revenue of EUR 13.2 million in the period from July 1 to September 30, 2024 (Q3) (same period of the previous year: EUR 5.9 million), a year-on-year increase of 130 %
  • Profitable growth is stabilizing: EBITDA of between EUR 0.9 million and EUR 1.1 million in the third quarter of 2024
  • Revenue of at least EUR 40 million expected for the full year 2024

Berlin, October 10, 2024 – Cantourage Group SE (hereinafter referred to as “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe’s leading publicly listed cannabis company, generated revenue of EUR 13.2 million in the period from July 1 to September 30, 2024, setting a new record quarter in the company’s history. Last month, the company announced that it had exceeded its total annual revenue for 2023 (EUR 23.6 million) in the period from January 1 to August 30, 2024, by posting revenue of EUR 24.9 million. Yet another positive EBITDA in the range of EUR 0.9 million to EUR 1.1 million in the third quarter of 2024 shows that Cantourage is able to convert the current developments in the European medical cannabis markets into sustainable, profitable growth. Revenue of at least EUR 40 million is expected for the full year 2024.

“It is important for investors to realize that the only areas in Germany and Europe in which truly profitable and growing business models can be established and monetized are those related to medical cannabis. I am not aware of any German company that is growing significantly and operating profitably with seeds, cuttings and non-commercial association structures,” said Philip Schetter, CEO of Cantourage.

Cantourage thus confirms the positive business development since the partial legalization of cannabis on April 1, 2024, although legalization for recreational use in Germany faces serious challenges. The cultivation associations (“cannabis clubs”) are facing massive bureaucratic headwinds, with the result that only very few of them have been able to start operations to date – and the future prospects are more than questionable. The so-called “Pillar 2” of the Cannabis Act, which was intended to lay the foundation for a real recreational market, was recently buried for the current legislative period even by the biggest legalization advocates in the federal government.

As unclear as the situation in the recreational sector is, the medical cannabis market in Germany is currently growing steadily. On April 1, 2024, cannabis was also removed from the Narcotics Act in a therapeutic context, which massively simplifies the process for everyone involved – from importers to doctors and pharmacies to patients. This has led to an unprecedented demand for medical cannabis, which Cantourage brings to Europe from many cultivation companies worldwide.

“The real legalization of recreational cannabis that contains THC, as is the case in North America, for example, is off the table here for the time being. Nevertheless, medical cannabis is here to stay and will continue to grow.
We are pleased that so many people in Germany have found their way to cannabis therapy in the past few months. This development will definitely continue in the future. Millions of cannabis users who have so far treated themselves for sleep disorders, pain or other widespread diseases – and have often resorted to unsafe products from the black market for this purpose – can now access safe preparations in pharmaceutical quality. We deliver these products through our flexible and efficient sourcing model, which we can and will continue to scale up in the months ahead. One thing is clear to us: regardless of what happens in the recreational market, the medical market will play the leading role in the years to come in ensuring that people in Germany and other European countries have access to safe, tested cannabis,” emphasizes Philip Schetter, CEO of Cantourage.

 

About Cantourage

Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH.”

Further information: www.cantourage.com

 

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

 

Press contact at Cantourage:

Frederick Steudemann
Tel. +49 (0)30 4701 350 - 50
steudemann@cantourage.com



10.10.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2005489

 
End of News EQS News Service

2005489  10.10.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2005489&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL. 

Die wichtigsten Finanzdaten auf einen Blick
  2018 2019 2020 2021 2022 2023 2024e
Umsatzerlöse1 0,00 0,00 0,53 5,22 14,16 23,56 48,00
EBITDA1,2 0,00 0,00 -0,56 -0,83 -2,51 -0,25 3,60
EBITDA-Marge3 0,00 0,00 -105,66 -15,90 -17,73 -1,06 7,50
EBIT1,4 0,00 0,00 -0,59 -0,97 -6,32 -4,33 -0,40
EBIT-Marge5 0,00 0,00 -111,32 -18,58 -44,63 -18,38 -0,83
Jahresüberschuss1 0,00 0,00 -0,59 -0,97 -5,92 4,27 -0,05
Netto-Marge6 0,00 0,00 -111,32 -18,58 -41,81 18,12 -0,10
Cashflow1,7 0,00 0,00 -0,56 -0,83 -2,11 -0,20 0,00
Ergebnis je Aktie8 0,00 0,00 -0,05 -0,08 -0,47 -0,34 -0,01
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben
Legende

1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PKF Wulf Gruppe

Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.

INVESTOR-INFORMATIONEN
©boersengefluester.de
Cantourage Group
WKN ISIN Rechtsform Börsenwert IPO Einschätzung Plus Code
A3DSV0 DE000A3DSV01 SE 64,21 Mio € 11.11.2022 Kaufen 9F4MF9M4+93
* * *
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV KBV KCV KUV
57,22 36,78 1,56 -51,50 1,60 -77,83 2,73
Dividenden
Dividende '2022
in €
Dividende '2023
in €
Dividende '2024e
in €
Div.-Rendite '2024e
in %
0,00 0,00 0,00 0,00%
Finanztermine
Hauptversammlung Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.06.2024 15.05.2024 09.07.2024 07.11.2024 06.06.2024
Performance-Angaben
Abstand 60-Tage-Linie Abstand 200-Tage-Linie Performance YtD Kursveränderung 52 Wochen IPO
Akt. Kurs (EoD)
-1,90%
5,15 €
ATH 40,50 €
+7,92% -15,30% -28,27% -27,67% -20,52%

Werbung ist für uns ein wichtiger Einnahmekanal. Aber wir verstehen, dass sie manchmal lästig wird. Wenn Sie die Anzahl der angezeigten Werbung reduzieren möchten, loggen Sie sich einfach in Ihr Benutzerkonto ein und verwalten Sie die Einstellungen von dort aus. Als registrierter Benutzer erhalten Sie viele Vorteile.
          Qualitätsjournalismus · 2013-2024 · Made in Germany          
Die Nachrichtenmanufaktur

Informierte Anleger treffen bessere Entscheidungen

Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.

Kontakt

Idee & Konzept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 von Gereon Kruse #BGFL